WASHINGTON, Oct 24 (Reuters) - U.S. regulators have reprimanded Sanofi-Aventis (SASY.PA: Quote, Profile, Research) for shoddy oversight of investigators doing a clinical study of its antibiotic drug Ketek, said a letter released by the government on Wednesday.
